Similar results were reported in another Chinese cohort, where the prevalence of anti-TIF1-γ antibodies was significantly higher in CAM patients (46.9%) than in myositis patients without concomitant malignancy (14.8%) [62]. The gene discussed is TRIM33; the disease is myositis disease.